STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $110,919 | +42.8% | 28,152 | +285.4% | 0.00% | – |
Q2 2023 | $77,652 | -13.5% | 7,305 | -32.2% | 0.00% | – |
Q1 2023 | $89,797 | -69.2% | 10,780 | -65.8% | 0.00% | – |
Q4 2022 | $291,336 | -99.9% | 31,564 | +84.5% | 0.00% | – |
Q3 2022 | $219,718,000 | +15.7% | 17,112 | +19.0% | 0.00% | – |
Q2 2022 | $189,907,000 | +448.4% | 14,376 | +773.9% | 0.00% | – |
Q1 2022 | $34,627,000 | -64.5% | 1,645 | -59.6% | 0.00% | – |
Q4 2021 | $97,663,000 | -76.3% | 4,071 | -74.9% | 0.00% | -100.0% |
Q3 2021 | $412,179,000 | +1624.7% | 16,202 | +2182.0% | 0.00% | – |
Q2 2021 | $23,899,000 | -85.3% | 710 | -83.0% | 0.00% | – |
Q1 2021 | $162,623,000 | +34.5% | 4,187 | +114.5% | 0.00% | – |
Q4 2020 | $120,887,000 | +24.6% | 1,952 | -32.6% | 0.00% | – |
Q3 2020 | $96,987,000 | +469.2% | 2,896 | +305.0% | 0.00% | – |
Q2 2020 | $17,038,000 | -85.7% | 715 | -86.3% | 0.00% | – |
Q1 2020 | $119,538,000 | +234.5% | 5,220 | +313.6% | 0.00% | – |
Q4 2019 | $35,740,000 | +43.6% | 1,262 | +9.0% | 0.00% | – |
Q3 2019 | $24,885,000 | – | 1,158 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |